CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Biotage - BIOT CFD

174.8
2.7%
1.9
Low: 167.8
High: 175.4
Market Trading Hours* (UTC) Opens on Monday at 08:10

Mon - Fri: 08:10 - 16:25

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 1.9
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025632 %
Charges from borrowed part ($-1.03)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025632%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.018813 %
Charges from borrowed part ($-0.75)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.018813%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency SEK
Margin 20%
Stock exchange Sweden
Commission on trade 0%

*Information provided by Capital.com

Biotage AB ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 170.2
Open* 168.1
1-Year Change* -13.26%
Day's Range* 167.8 - 175.4
52 wk Range 149.80-239.40
Average Volume (10 days) 67.05K
Average Volume (3 months) 1.85M
Market Cap 11.60B
P/E Ratio 48.66
Shares Outstanding 65.98M
Revenue 1.52B
EPS 3.61
Dividend (Yield %) 0.88168
Beta 1.22
Next Earnings Date Feb 15, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 3, 2023 174.8 6.6 3.92% 168.2 175.5 166.7
Feb 2, 2023 170.2 5.9 3.59% 164.3 171.7 163.2
Feb 1, 2023 161.8 1.3 0.81% 160.5 163.7 159.9
Jan 31, 2023 159.9 1.5 0.95% 158.4 160.5 157.0
Jan 30, 2023 160.3 -0.9 -0.56% 161.2 161.8 157.5
Jan 27, 2023 161.8 2.7 1.70% 159.1 162.3 159.1
Jan 26, 2023 160.5 3.7 2.36% 156.8 162.0 156.8
Jan 25, 2023 158.5 1.8 1.15% 156.7 158.5 154.8
Jan 24, 2023 157.3 1.1 0.70% 156.2 162.7 155.5
Jan 23, 2023 156.2 1.8 1.17% 154.4 157.9 153.9
Jan 20, 2023 152.2 1.0 0.66% 151.2 153.7 147.6
Jan 19, 2023 152.7 -2.8 -1.80% 155.5 157.6 150.9
Jan 18, 2023 156.8 -7.5 -4.56% 164.3 165.4 152.6
Jan 17, 2023 172.4 1.9 1.11% 170.5 172.9 168.5
Jan 16, 2023 173.8 -1.9 -1.08% 175.7 176.1 170.0
Jan 13, 2023 175.1 -1.8 -1.02% 176.9 177.2 171.3
Jan 12, 2023 170.5 -3.5 -2.01% 174.0 175.5 169.2
Jan 11, 2023 174.0 0.5 0.29% 173.5 177.2 172.4
Jan 10, 2023 173.5 0.7 0.41% 172.8 175.6 171.4
Jan 9, 2023 173.9 -0.6 -0.34% 174.5 177.1 172.1

Biotage Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 667.912 748.147 910.896 1101.37 1092.28 1232
Revenue 667.912 748.147 910.896 1101.37 1092.28 1232
Cost of Revenue, Total 282.098 291.483 354.27 415.963 425.55 477
Gross Profit 385.814 456.664 556.626 685.41 666.728 755
Total Operating Expense 568.798 614.517 738.418 893.253 886.093 961
Selling/General/Admin. Expenses, Total 237.338 254.497 313.127 360.028 336.94 374
Research & Development 17.326 33.581 43.101 49.733 44.102 56
Depreciation / Amortization 39.795 30.241 34.032 65.132 66.449 65
Interest Expense (Income) - Net Operating -7.004 -8.309 -14.681 -2.41 -19.352 -16
Unusual Expense (Income) 0 2.5 2.5
Other Operating Expenses, Total -0.755 13.024 6.069 2.307 32.404 5
Operating Income 99.114 133.63 172.478 208.12 206.185 271
Interest Income (Expense), Net Non-Operating -6.713 2.63 3.811 3.949 -8.901 -12
Other, Net 0 0 0 -0.077 25.445 10
Net Income Before Taxes 92.401 136.26 176.289 211.992 222.729 269
Net Income After Taxes 92.795 138.747 167.627 186.82 175.331 205
Net Income Before Extra. Items 92.795 138.747 167.627 186.82 175.331 205
Net Income 92.795 138.747 167.627 186.82 175.331 205
Total Adjustments to Net Income 0.001
Income Available to Common Excl. Extra. Items 92.796 138.747 167.627 186.82 175.331 205
Income Available to Common Incl. Extra. Items 92.796 138.747 167.627 186.82 175.331 205
Diluted Net Income 92.796 138.747 167.627 186.82 175.331 205
Diluted Weighted Average Shares 64.7144 64.7144 64.7144 65.1821 65.2085 65.4648
Diluted EPS Excluding Extraordinary Items 1.43393 2.14399 2.59026 2.86612 2.68877 3.13145
Dividends per Share - Common Stock Primary Issue 1.25 1.4 1.5 0 1.5 1.55
Diluted Normalized EPS 1.43393 2.14399 2.62699 2.89992 2.68877 3.17802
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 281.35 303.458 305 342 386
Revenue 281.35 303.458 305 342 386
Cost of Revenue, Total 103.889 121.281 122 130 145
Gross Profit 177.461 182.177 183 212 241
Total Operating Expense 201.972 240.943 237 281 290
Selling/General/Admin. Expenses, Total 86.447 94.618 100 123 122
Research & Development 19.389 23.065 19 29 25
Other Operating Expenses, Total -7.753 1.979 -4 -1 -2
Operating Income 79.378 62.515 68 61 96
Interest Income (Expense), Net Non-Operating -2.166 -1.94 -2 4 -4
Net Income Before Taxes 77.212 60.575 66 65 92
Net Income After Taxes 60.039 45.973 53 46 71
Net Income Before Extra. Items 60.039 45.973 53 46 71
Net Income 60.039 45.973 53 46 71
Total Adjustments to Net Income 0.001
Income Available to Common Excl. Extra. Items 60.04 45.973 53 46 71
Income Available to Common Incl. Extra. Items 60.04 45.973 53 46 71
Diluted Net Income 60.04 45.973 53 46 71
Diluted Weighted Average Shares 65.2304 65.2674 65.3455 66.016 65.9838
Diluted EPS Excluding Extraordinary Items 0.92043 0.70438 0.81107 0.6968 1.07602
Dividends per Share - Common Stock Primary Issue 0 0 0 1.55 0
Diluted Normalized EPS 0.92043 0.72531 0.81353 0.70752 1.07602
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 355.98 409.252 494.438 586.569 751.615 774
Cash and Short Term Investments 128.622 174.263 177.02 185.867 371.325 311
Cash & Equivalents 128.622 174.263 177.02 185.867 371.325 311
Total Receivables, Net 130.89 128.939 173.728 212.815 207.455 207
Accounts Receivable - Trade, Net 118.348 118.191 156.042 197.651 194.018 180
Total Inventory 88.906 95.794 132.338 173.76 159.823 237
Prepaid Expenses 7.561 10.256 11.352 14.128 13.013 19
Other Current Assets, Total 0.001 -0.001 -0.001
Total Assets 695.196 757.201 1003.2 1335.69 1434.44 1992
Property/Plant/Equipment, Total - Net 45.447 45.303 48.63 112.253 103.656 128
Property/Plant/Equipment, Total - Gross 120.207 128.483 130.51 215.717 201.79 324
Accumulated Depreciation, Total -74.76 -83.18 -81.88 -103.464 -98.134 -196
Goodwill, Net 104.023 104.023 186.055 315.869 290.209 741
Intangibles, Net 116.015 118.646 192.654 260.047 250.787 313
Long Term Investments 18.645 17.838 17.368 16.614 12.254 14
Note Receivable - Long Term 1.156 0 0.003
Other Long Term Assets, Total 53.93 62.139 64.055 44.335 25.92 22
Total Current Liabilities 127.721 144.377 173.397 212.272 217.364 313
Accounts Payable 38.133 47.457 54.764 41.461 51.236 56
Payable/Accrued -0.001 0.001
Accrued Expenses 47.103 50.561 60.411 69.334 58.479
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 21.231 21.214 23
Other Current Liabilities, Total 42.486 46.359 58.222 80.245 86.435 234
Total Liabilities 131.958 148.59 301.023 460.184 444.403 621
Total Long Term Debt 0 0 109.4 147.647 140.677 180
Deferred Income Tax 1.759 1.621 14.78 28.884 32.838 73
Other Liabilities, Total 2.478 2.592 3.446 71.381 53.524 55
Total Equity 563.238 608.611 702.18 875.503 990.038 1371
Common Stock 89.953 89.953 89.953 90.63 90.969 92
Retained Earnings (Accumulated Deficit) 557.223 615.077 692.104 781.121 956.114 1063
Other Equity, Total -83.938 -96.419 -79.877 3.752 -116.547 -50
Total Liabilities & Shareholders’ Equity 695.196 757.201 1003.2 1335.69 1434.44 1992
Total Common Shares Outstanding 64.7144 64.7144 64.7144 64.7144 65.2018 65.9838
Long Term Debt 109.4 109.55 110 150
Capital Lease Obligations 38.097 30.677 30
Additional Paid-In Capital 59.502 266
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 851.273 694.254 784 774 842
Cash and Short Term Investments 422.068 278.552 359 311 349
Cash & Equivalents 422.068 278.552 359 311 349
Total Receivables, Net 237.214 221.377 217 226 249
Accounts Receivable - Trade, Net 204.607 191.724 181 226 216
Total Inventory 191.992 194.326 208 237 244
Other Current Assets, Total -0.001 -0.001
Total Assets 1575.81 1409.61 1503 1992 2056
Property/Plant/Equipment, Total - Net 126.05 125.751 124 128 126
Goodwill, Net 302.381 297.524 304 741 746
Intangibles, Net 259.79 257.747 257 313 309
Long Term Investments 12.263 12.224 12 14 15
Other Long Term Assets, Total 24.051 22.115 22 22 18
Total Current Liabilities 246.435 263.719 289 313 298
Accounts Payable 53.503 46.03 54 56 43
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 22.653 23.289 24 23 23
Other Current Liabilities, Total 170.279 194.4 211 234 232
Total Liabilities 493.496 390.115 413 621 601
Total Long Term Debt 153.626 40.861 37 180 175
Long Term Debt 110 0 0 150 150
Capital Lease Obligations 43.626 40.861 37 30 25
Deferred Income Tax 36.325 36.86 37 73 72
Other Liabilities, Total 57.11 48.675 50 55 56
Total Equity 1082.31 1019.5 1090 1371 1455
Common Stock 90.969 90.969 91 92 92
Additional Paid-In Capital 60.137 61.239 64 266 269
Retained Earnings (Accumulated Deficit) 1016.15 964.324 1017 1063 1134
Other Equity, Total -84.948 -97.032 -82 -50 -40
Total Liabilities & Shareholders’ Equity 1575.81 1409.61 1503 1992 2056
Total Common Shares Outstanding 65.2018 65.2018 65.2018 65.9838 65.9838
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 92.401 136.26 176.289 211.992 222.729 269
Cash From Operating Activities 139.072 168.932 155.005 211.807 279.047 353
Cash From Operating Activities 43.836 34.225 39.412 74.372 73.904 75
Non-Cash Items -1.187 1.991 -11.727 2.129 -11.661 4
Cash Taxes Paid 5.363 5.091 9.314 9.925 15.083 16
Cash Interest Paid 0.023 0.002 1.738 2.86 3.339 3
Changes in Working Capital 4.022 -3.544 -48.969 -76.686 -5.925 5
Cash From Investing Activities -67.726 -36.903 -178.411 -85.676 -61.32 -341
Capital Expenditures -47.54 -37.804 -47.158 -45.454 -60.941 -56
Other Investing Cash Flow Items, Total -20.186 0.901 -131.253 -40.222 -0.379 -285
Cash From Financing Activities -81.152 -81.053 19.342 -119.205 -22.723 -82
Total Cash Dividends Paid -80.893 -80.893 -90.6 -97.803 0 -98
Issuance (Retirement) of Debt, Net -0.259 -0.16 109.942 -21.402 -22.723 16
Foreign Exchange Effects 3.544 -5.336 6.821 1.921 -9.547 9
Net Change in Cash -6.262 45.64 2.757 8.847 185.457 -61
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 77.212 137.787 204 269 92
Cash From Operating Activities 67.62 159.904 249 353 57
Cash From Operating Activities 17.133 35.656 54 75 23
Non-Cash Items -1.912 -2.579 -5 4 5
Cash Taxes Paid 4.569 8.686 14 16 15
Changes in Working Capital -24.813 -10.96 -4 5 -63
Cash From Investing Activities -18.266 -34.637 -45 -341 -14
Capital Expenditures -18.266 -34.137 -44 -56 -14
Other Investing Cash Flow Items, Total 0 -0.5 -1 -285 0
Cash From Financing Activities -5.17 -223.759 -227 -82 -6
Issuance (Retirement) of Debt, Net -5.17 -125.956 -129 16 -6
Foreign Exchange Effects 6.559 5.719 10 9 2
Net Change in Cash 50.743 -92.773 -13 -61 39
Total Cash Dividends Paid -97.803 -98 -98 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
SEB Investment Management AB Investment Advisor 7.55 4981775 -6598 2022-12-31 LOW
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund 6.84 4513290 -1505315 2022-12-31 LOW
Invesco Advisers, Inc. Investment Advisor 5.75 3794067 -41121 2022-12-31 LOW
ODIN Forvaltning AS Investment Advisor 4.5 2969270 -30730 2022-12-31 LOW
Didner & Gerge Fonder AB Investment Advisor 3.75 2474392 1493504 2022-12-31 LOW
Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 3.56 2349022 -131968 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.39 2236850 52787 2022-12-31 LOW
Lannebo Fonder AB Investment Advisor/Hedge Fund 3.24 2137874 -26564 2022-12-31 LOW
Tredje AP Fonden Pension Fund 3.1 2045497 310124 2022-12-31 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.31 1524225 -6599 2022-12-31 LOW
Första AP-Fonden Pension Fund 1.99 1313077 -257337 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.86 1227298 59385 2022-12-31 LOW
TIN Fonder Investment Advisor 1.53 1009552 -10412 2022-12-31 MED
Montanaro Asset Management Limited Investment Advisor 1.37 903978 219232 2022-12-31 LOW
M & G Investment Management Ltd. Investment Advisor 1.25 824797 0 2022-12-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.14 752215 -39590 2022-09-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 1.0636 701784 -154 2022-11-30 LOW
DNCA Investments Investment Advisor 0.9396 620000 -50224 2022-12-31 LOW
Danske Bank Asset Management Investment Advisor 0.9353 617175 15262 2022-12-31 LOW
Nordea Funds Oy Investment Advisor 0.8444 557198 -45107 2022-12-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Biotage Company profile

Biotage is a Sweden-based Life Science company, specialising in separation and synthesis solutions. The company’s offering comprises three distinct product lines. The Organic Chemistry line seeks to rationalise the development of drugs by purifying substances that will become new drugs. The Analytical Chemistry line aims to reinvent the sample analysis. The Industrial Product line offers innovative systems and consumables that separate substances during the large-scale production. All product lines are available across Europe and the US by the Biotage sales organisation or by distributors. Headquartered in Uppsala, Sweden, Biotage trades on the NASDAQ Stockholm under the BIOT ticker. Find out the latest BIOT stock news at Capital.com.
Industry: Medical Diagnostic & Testing Equipment

Vimpelgatan 5
UPPSALA
UPPSALA 753 18
SE

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

73.41 Price
-3.570% 1D Chg, %
Long position overnight fee -0.0223%
Short position overnight fee 0.0065%
Overnight fee time 22:00 (UTC)
Spread 0.03

XRP/USD

0.41 Price
-0.060% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00274

US100

12,566.80 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0183%
Short position overnight fee 0.0071%
Overnight fee time 22:00 (UTC)
Spread 3.0

Natural Gas

2.41 Price
-2.390% 1D Chg, %
Long position overnight fee -0.1138%
Short position overnight fee 0.0796%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading